Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids

Inhaled glucocorticoids are pivotal in maintenance therapy of chronic bronchial asthma; however, conflict exists over their effects on bone and mineral metabolism. We measured bone mineral density (BMD), bone turnover markers, and adrenal steroid hormones in 53 patients (34 female, 19 male) with chr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral research 1998-08, Vol.13 (8), p.1283-1289
Hauptverfasser: Ebeling, Peter R., Erbas, Bircan, Hopper, John L., Wark, John D., Rubinfeld, A. Roman
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1289
container_issue 8
container_start_page 1283
container_title Journal of bone and mineral research
container_volume 13
creator Ebeling, Peter R.
Erbas, Bircan
Hopper, John L.
Wark, John D.
Rubinfeld, A. Roman
description Inhaled glucocorticoids are pivotal in maintenance therapy of chronic bronchial asthma; however, conflict exists over their effects on bone and mineral metabolism. We measured bone mineral density (BMD), bone turnover markers, and adrenal steroid hormones in 53 patients (34 female, 19 male) with chronic bronchial asthma who had taken either inhaled beclomethasone or budesonide in doses of ≥ 1500 μg/day for at least 12 months to determine pathogenetic mechanisms of bone loss. To account for the effect of prior oral glucocorticoid exposure we divided patients into two groups: one with (OG) and the other without (IG) a past history of maintenance (> 1 month) oral glucocorticoid therapy. Lumbar spine (LS) and proximal femur BMDs were ∼1 SD lower in men and women taking OG or high‐dose IG for chronic bronchial asthma, potentially equivalent to a doubling of the risk of fracture at these sites. Prior exposure to OG in women was also associated with lower LS and proximal femur BMDs, while men were more sensitive to the adverse effects of IG on LS and Ward's triangle BMDs. Bone formation markers were decreased; however, bone resorption marker concentrations were normal. All patients had evidence of suppression of both endogenous glucocorticoid and adrenal androgen production. Both total duration of OG and biochemical bone turnover marker concentrations were negatively related to proximal femur and rib BMDs and total body bone mineral content, but not to LS BMD. These were stronger for bone resorption markers. Uncoupling of ongoing normal bone resorption from suppressed bone formation may therefore contribute to glucocorticoid‐associated bone loss in asthma. Adrenal androgen suppression may also increase the susceptibility of postmenopausal women in particular to bone loss with OG. Although the effects of high‐dose IG on BMD are associated with lower LS BMD in men, this observation should now be investigated further in prospective studies.
doi_str_mv 10.1359/jbmr.1998.13.8.1283
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17145219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17145219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4160-cb862c566a090cef6308f1f8da8ab4c9ea8e52d8857a344516e03d620dc22223</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhi0EKkvhCRCSD4hbFk8ce-0TakspRVtVQrlbXmfCukrsYidUe-MR-ow8CV521TM-jDX6__nH-kzIW2BL4EJ_vNuMaQlaq9IuS6kVf0YWIGpeNVLBc7JgSjUVazi8JK9yvmOMSSHlCTnRK1CgVwsynseA9MYHTHagnzFkP-2oDR39J7RzCvEXJuoDPcvTdrSTd5m2Ce2EHX3w05auY_jx5_dji2mk12FrhyLERG_3gVfD7KKLqUxF3-XX5EVvh4xvjvcpab9cthdfq_Xt1fXF2bpyDUhWuY2StSsvtUwzh73kTPXQq84qu2mcRqtQ1J1SYmV50wiQyHgna9a5uhx-Sj4cYu9T_Dljnszos8NhsAHjnA2soBE16GLkB6NLMeeEvblPfrRpZ4CZPWOzZ2z2jEtrSimMy9S7Y_y8GbF7mjlCLfr7o26zs0OfbHA-P9lqrqF8RLF9Otge_IC7_9lsvp3ffBdSMChAgPG_JVyZjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17145219</pqid></control><display><type>article</type><title>Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Ebeling, Peter R. ; Erbas, Bircan ; Hopper, John L. ; Wark, John D. ; Rubinfeld, A. Roman</creator><creatorcontrib>Ebeling, Peter R. ; Erbas, Bircan ; Hopper, John L. ; Wark, John D. ; Rubinfeld, A. Roman</creatorcontrib><description>Inhaled glucocorticoids are pivotal in maintenance therapy of chronic bronchial asthma; however, conflict exists over their effects on bone and mineral metabolism. We measured bone mineral density (BMD), bone turnover markers, and adrenal steroid hormones in 53 patients (34 female, 19 male) with chronic bronchial asthma who had taken either inhaled beclomethasone or budesonide in doses of ≥ 1500 μg/day for at least 12 months to determine pathogenetic mechanisms of bone loss. To account for the effect of prior oral glucocorticoid exposure we divided patients into two groups: one with (OG) and the other without (IG) a past history of maintenance (&gt; 1 month) oral glucocorticoid therapy. Lumbar spine (LS) and proximal femur BMDs were ∼1 SD lower in men and women taking OG or high‐dose IG for chronic bronchial asthma, potentially equivalent to a doubling of the risk of fracture at these sites. Prior exposure to OG in women was also associated with lower LS and proximal femur BMDs, while men were more sensitive to the adverse effects of IG on LS and Ward's triangle BMDs. Bone formation markers were decreased; however, bone resorption marker concentrations were normal. All patients had evidence of suppression of both endogenous glucocorticoid and adrenal androgen production. Both total duration of OG and biochemical bone turnover marker concentrations were negatively related to proximal femur and rib BMDs and total body bone mineral content, but not to LS BMD. These were stronger for bone resorption markers. Uncoupling of ongoing normal bone resorption from suppressed bone formation may therefore contribute to glucocorticoid‐associated bone loss in asthma. Adrenal androgen suppression may also increase the susceptibility of postmenopausal women in particular to bone loss with OG. Although the effects of high‐dose IG on BMD are associated with lower LS BMD in men, this observation should now be investigated further in prospective studies.</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1359/jbmr.1998.13.8.1283</identifier><identifier>PMID: 9718197</identifier><identifier>CODEN: JBMREJ</identifier><language>eng</language><publisher>Washington, DC: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</publisher><subject>Absorptiometry, Photon ; Administration, Inhalation ; Adolescent ; Adult ; Aged ; Asthma - drug therapy ; Beclomethasone - administration &amp; dosage ; Beclomethasone - adverse effects ; Biological and medical sciences ; Biomarkers - blood ; Bone Density - drug effects ; Budesonide - administration &amp; dosage ; Budesonide - adverse effects ; Dehydroepiandrosterone Sulfate - blood ; Drug toxicity and drugs side effects treatment ; Female ; Femur ; Glucocorticoids - administration &amp; dosage ; Glucocorticoids - adverse effects ; Humans ; Hydrocortisone - blood ; Lumbar Vertebrae ; Male ; Medical sciences ; Middle Aged ; Osteoporosis - blood ; Osteoporosis - chemically induced ; Osteoporosis - diagnostic imaging ; Pharmacology. Drug treatments ; Ribs ; Toxicity: osteoarticular system</subject><ispartof>Journal of bone and mineral research, 1998-08, Vol.13 (8), p.1283-1289</ispartof><rights>Copyright © 1998 ASBMR</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4160-cb862c566a090cef6308f1f8da8ab4c9ea8e52d8857a344516e03d620dc22223</citedby><cites>FETCH-LOGICAL-c4160-cb862c566a090cef6308f1f8da8ab4c9ea8e52d8857a344516e03d620dc22223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1359%2Fjbmr.1998.13.8.1283$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1359%2Fjbmr.1998.13.8.1283$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2391006$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9718197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebeling, Peter R.</creatorcontrib><creatorcontrib>Erbas, Bircan</creatorcontrib><creatorcontrib>Hopper, John L.</creatorcontrib><creatorcontrib>Wark, John D.</creatorcontrib><creatorcontrib>Rubinfeld, A. Roman</creatorcontrib><title>Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>Inhaled glucocorticoids are pivotal in maintenance therapy of chronic bronchial asthma; however, conflict exists over their effects on bone and mineral metabolism. We measured bone mineral density (BMD), bone turnover markers, and adrenal steroid hormones in 53 patients (34 female, 19 male) with chronic bronchial asthma who had taken either inhaled beclomethasone or budesonide in doses of ≥ 1500 μg/day for at least 12 months to determine pathogenetic mechanisms of bone loss. To account for the effect of prior oral glucocorticoid exposure we divided patients into two groups: one with (OG) and the other without (IG) a past history of maintenance (&gt; 1 month) oral glucocorticoid therapy. Lumbar spine (LS) and proximal femur BMDs were ∼1 SD lower in men and women taking OG or high‐dose IG for chronic bronchial asthma, potentially equivalent to a doubling of the risk of fracture at these sites. Prior exposure to OG in women was also associated with lower LS and proximal femur BMDs, while men were more sensitive to the adverse effects of IG on LS and Ward's triangle BMDs. Bone formation markers were decreased; however, bone resorption marker concentrations were normal. All patients had evidence of suppression of both endogenous glucocorticoid and adrenal androgen production. Both total duration of OG and biochemical bone turnover marker concentrations were negatively related to proximal femur and rib BMDs and total body bone mineral content, but not to LS BMD. These were stronger for bone resorption markers. Uncoupling of ongoing normal bone resorption from suppressed bone formation may therefore contribute to glucocorticoid‐associated bone loss in asthma. Adrenal androgen suppression may also increase the susceptibility of postmenopausal women in particular to bone loss with OG. Although the effects of high‐dose IG on BMD are associated with lower LS BMD in men, this observation should now be investigated further in prospective studies.</description><subject>Absorptiometry, Photon</subject><subject>Administration, Inhalation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Asthma - drug therapy</subject><subject>Beclomethasone - administration &amp; dosage</subject><subject>Beclomethasone - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Bone Density - drug effects</subject><subject>Budesonide - administration &amp; dosage</subject><subject>Budesonide - adverse effects</subject><subject>Dehydroepiandrosterone Sulfate - blood</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Femur</subject><subject>Glucocorticoids - administration &amp; dosage</subject><subject>Glucocorticoids - adverse effects</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Lumbar Vertebrae</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteoporosis - blood</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - diagnostic imaging</subject><subject>Pharmacology. Drug treatments</subject><subject>Ribs</subject><subject>Toxicity: osteoarticular system</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhi0EKkvhCRCSD4hbFk8ce-0TakspRVtVQrlbXmfCukrsYidUe-MR-ow8CV521TM-jDX6__nH-kzIW2BL4EJ_vNuMaQlaq9IuS6kVf0YWIGpeNVLBc7JgSjUVazi8JK9yvmOMSSHlCTnRK1CgVwsynseA9MYHTHagnzFkP-2oDR39J7RzCvEXJuoDPcvTdrSTd5m2Ce2EHX3w05auY_jx5_dji2mk12FrhyLERG_3gVfD7KKLqUxF3-XX5EVvh4xvjvcpab9cthdfq_Xt1fXF2bpyDUhWuY2StSsvtUwzh73kTPXQq84qu2mcRqtQ1J1SYmV50wiQyHgna9a5uhx-Sj4cYu9T_Dljnszos8NhsAHjnA2soBE16GLkB6NLMeeEvblPfrRpZ4CZPWOzZ2z2jEtrSimMy9S7Y_y8GbF7mjlCLfr7o26zs0OfbHA-P9lqrqF8RLF9Otge_IC7_9lsvp3ffBdSMChAgPG_JVyZjQ</recordid><startdate>199808</startdate><enddate>199808</enddate><creator>Ebeling, Peter R.</creator><creator>Erbas, Bircan</creator><creator>Hopper, John L.</creator><creator>Wark, John D.</creator><creator>Rubinfeld, A. Roman</creator><general>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</general><general>American Society for Bone and Mineral Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>199808</creationdate><title>Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids</title><author>Ebeling, Peter R. ; Erbas, Bircan ; Hopper, John L. ; Wark, John D. ; Rubinfeld, A. Roman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4160-cb862c566a090cef6308f1f8da8ab4c9ea8e52d8857a344516e03d620dc22223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Absorptiometry, Photon</topic><topic>Administration, Inhalation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Asthma - drug therapy</topic><topic>Beclomethasone - administration &amp; dosage</topic><topic>Beclomethasone - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Bone Density - drug effects</topic><topic>Budesonide - administration &amp; dosage</topic><topic>Budesonide - adverse effects</topic><topic>Dehydroepiandrosterone Sulfate - blood</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Femur</topic><topic>Glucocorticoids - administration &amp; dosage</topic><topic>Glucocorticoids - adverse effects</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Lumbar Vertebrae</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteoporosis - blood</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - diagnostic imaging</topic><topic>Pharmacology. Drug treatments</topic><topic>Ribs</topic><topic>Toxicity: osteoarticular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebeling, Peter R.</creatorcontrib><creatorcontrib>Erbas, Bircan</creatorcontrib><creatorcontrib>Hopper, John L.</creatorcontrib><creatorcontrib>Wark, John D.</creatorcontrib><creatorcontrib>Rubinfeld, A. Roman</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebeling, Peter R.</au><au>Erbas, Bircan</au><au>Hopper, John L.</au><au>Wark, John D.</au><au>Rubinfeld, A. Roman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>1998-08</date><risdate>1998</risdate><volume>13</volume><issue>8</issue><spage>1283</spage><epage>1289</epage><pages>1283-1289</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><coden>JBMREJ</coden><abstract>Inhaled glucocorticoids are pivotal in maintenance therapy of chronic bronchial asthma; however, conflict exists over their effects on bone and mineral metabolism. We measured bone mineral density (BMD), bone turnover markers, and adrenal steroid hormones in 53 patients (34 female, 19 male) with chronic bronchial asthma who had taken either inhaled beclomethasone or budesonide in doses of ≥ 1500 μg/day for at least 12 months to determine pathogenetic mechanisms of bone loss. To account for the effect of prior oral glucocorticoid exposure we divided patients into two groups: one with (OG) and the other without (IG) a past history of maintenance (&gt; 1 month) oral glucocorticoid therapy. Lumbar spine (LS) and proximal femur BMDs were ∼1 SD lower in men and women taking OG or high‐dose IG for chronic bronchial asthma, potentially equivalent to a doubling of the risk of fracture at these sites. Prior exposure to OG in women was also associated with lower LS and proximal femur BMDs, while men were more sensitive to the adverse effects of IG on LS and Ward's triangle BMDs. Bone formation markers were decreased; however, bone resorption marker concentrations were normal. All patients had evidence of suppression of both endogenous glucocorticoid and adrenal androgen production. Both total duration of OG and biochemical bone turnover marker concentrations were negatively related to proximal femur and rib BMDs and total body bone mineral content, but not to LS BMD. These were stronger for bone resorption markers. Uncoupling of ongoing normal bone resorption from suppressed bone formation may therefore contribute to glucocorticoid‐associated bone loss in asthma. Adrenal androgen suppression may also increase the susceptibility of postmenopausal women in particular to bone loss with OG. Although the effects of high‐dose IG on BMD are associated with lower LS BMD in men, this observation should now be investigated further in prospective studies.</abstract><cop>Washington, DC</cop><pub>John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)</pub><pmid>9718197</pmid><doi>10.1359/jbmr.1998.13.8.1283</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0884-0431
ispartof Journal of bone and mineral research, 1998-08, Vol.13 (8), p.1283-1289
issn 0884-0431
1523-4681
language eng
recordid cdi_proquest_miscellaneous_17145219
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals
subjects Absorptiometry, Photon
Administration, Inhalation
Adolescent
Adult
Aged
Asthma - drug therapy
Beclomethasone - administration & dosage
Beclomethasone - adverse effects
Biological and medical sciences
Biomarkers - blood
Bone Density - drug effects
Budesonide - administration & dosage
Budesonide - adverse effects
Dehydroepiandrosterone Sulfate - blood
Drug toxicity and drugs side effects treatment
Female
Femur
Glucocorticoids - administration & dosage
Glucocorticoids - adverse effects
Humans
Hydrocortisone - blood
Lumbar Vertebrae
Male
Medical sciences
Middle Aged
Osteoporosis - blood
Osteoporosis - chemically induced
Osteoporosis - diagnostic imaging
Pharmacology. Drug treatments
Ribs
Toxicity: osteoarticular system
title Bone Mineral Density and Bone Turnover in Asthmatics Treated with Long‐Term Inhaled or Oral Glucocorticoids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A28%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20Mineral%20Density%20and%20Bone%20Turnover%20in%20Asthmatics%20Treated%20with%20Long%E2%80%90Term%20Inhaled%20or%20Oral%20Glucocorticoids&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Ebeling,%20Peter%20R.&rft.date=1998-08&rft.volume=13&rft.issue=8&rft.spage=1283&rft.epage=1289&rft.pages=1283-1289&rft.issn=0884-0431&rft.eissn=1523-4681&rft.coden=JBMREJ&rft_id=info:doi/10.1359/jbmr.1998.13.8.1283&rft_dat=%3Cproquest_cross%3E17145219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17145219&rft_id=info:pmid/9718197&rfr_iscdi=true